Zobrazeno 1 - 10
of 303
pro vyhledávání: '"Benoit You"'
Autor:
Olivier Colomban, Elizabeth M. Swisher, Rebecca Kristeleit, Iain McNeish, Ronnie Shapira-Frommer, Sandra Goble, Kevin K. Lin, Lara Maloney, Gilles Freyer, Benoit You
Publikováno v:
EBioMedicine, Vol 89, Iss , Pp 104477- (2023)
Summary: Background: PARP inhibitors (PARPi) have revolutionized the management of advanced ovarian carcinoma, and were investigated as forefront treatment in recurrent disease. The objective was to explore if mathematical modeling of the early longi
Externí odkaz:
https://doaj.org/article/8424b6b7464c47abaf85ca637a1499c4
Autor:
Olivier Trédan, Maud Toulmonde, Christophe Le Tourneau, Laure Montane, Antoine Italiano, Isabelle Ray-Coquard, Christelle De La Fouchardière, François Bertucci, Anthony Gonçalves, Carlos Gomez-Roca, Benoit You, Valéry Attignon, Sandrine Boyault, Philippe A. Cassier, Armelle Dufresne, Séverine Tabone-Eglinger, Alain Viari, Emilie Sohier, Maud Kamal, Gwenaël Garin, Jean-Yves Blay, David Pérol
Publikováno v:
Cancers, Vol 15, Iss 13, p 3441 (2023)
Background: MOST-plus is a multicenter, randomized, open-label, adaptive Phase II trial evaluating the clinical benefit of targeted treatments matched to molecular alteration in advanced/metastatic solid tumors. Sorafenib was tested on patients with
Externí odkaz:
https://doaj.org/article/9252af336131459388bd3c930b52ed6c
Autor:
Magali Rebucci-Peixoto, Angélique Vienot, Olivier Adotevi, Marion Jacquin, Francois Ghiringhelli, Christelle de la Fouchardière, Benoit You, Tristan Maurina, Elsa Kalbacher, Fernando Bazan, Guillaume Meynard, Anne-Laure Clairet, Christine Fagnoni-Legat, Laurie Spehner, Adeline Bouard, Dewi Vernerey, Aurélia Meurisse, Stefano Kim, Christophe Borg, Laura Mansi
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundThere is a strong rational of using anti–programmed cell death protein-1 and its ligand (anti–PD-1/L1) antibodies in human papillomavirus (HPV)–induced cancers. However, anti–PD-1/L1 as monotherapy induces a limited number of object
Externí odkaz:
https://doaj.org/article/90ac113021e14bb9a976565c61b79c86
Autor:
Amine Souadka, Hajar Essangri, Mohammed Anass Majbar, Amine Benkabbou, Saber Boutayeb, Benoit You, Olivier Glehen, Raouf Mohsine, Naoual Bakrin
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundThe utility of heated intraperitoneal chemotherapy (HIPEC) in the management of epithelial ovarian cancer (EOC) has been assessed in several randomised clinical trials and meta-analyses, and it is still a subject of controversy. Therefore,
Externí odkaz:
https://doaj.org/article/fd906d5f79c945838c707dd39f7422d8
Autor:
Eleni Karamouza, Rosalind M. Glasspool, Caroline Kelly, Liz-Anne Lewsley, Karen Carty, Gunnar B. Kristensen, Josee-Lyne Ethier, Tatsuo Kagimura, Nozomu Yanaihara, Sabrina Chiara Cecere, Benoit You, Ingrid A. Boere, Eric Pujade-Lauraine, Isabelle Ray-Coquard, Cécile Proust-Lima, Xavier Paoletti
Publikováno v:
Cancers, Vol 15, Iss 6, p 1823 (2023)
(1) Background: Cancer antigen 125 (CA-125) is a protein produced by ovarian cancer cells that is used for patients’ monitoring. However, the best ways to analyze its decline and prognostic role are poorly quantified. (2) Methods: We leveraged indi
Externí odkaz:
https://doaj.org/article/3d6ea15b1a234135a95e0b9e7a424411
Autor:
Yutaro Kaneko, Ryo Hatano, Naoto Hirota, Nicolas Isambert, Véronique Trillet-Lenoir, Benoit You, Jérôme Alexandre, Gérard Zalcman, Fanny Valleix, Thomas Podoll, Yoshimi Umezawa, Seiichi Takao, Satoshi Iwata, Osamu Hosono, Tetsuo Taguchi, Taketo Yamada, Nam H. Dang, Kei Ohnuma, Eric Angevin, Chikao Morimoto
Publikováno v:
Biomarker Research, Vol 9, Iss 1, Pp 1-13 (2021)
Abstract Background The phase I trial of the humanized anti-CD26 monoclonal antibody YS110 for CD26-expressing tumors was conducted recently. The present study identifies a potential prognostic biomarker for CD26-targeted therapy based on the phase I
Externí odkaz:
https://doaj.org/article/869532e7d9924a45b065a8c40a83cd05
Autor:
Pascal Pujol, Kevin Yauy, Amandine Coffy, Nicolas Duforet-Frebourg, Sana Gabteni, Jean-Pierre Daurès, Frédérique Penault Llorca, Frédéric Thomas, Kevin Hughes, Clare Turnbull, Virginie Galibert, Chloé Rideau, Carole Corsini, Laetitia Collet, Benoit You, David Geneviève, Nicolas Philippe
Publikováno v:
Cancers, Vol 14, Iss 13, p 3266 (2022)
Background: Poly(ADP-ribose) polymerase 1 inhibitor (PARPi) agents can improve progression-free survival of patients with breast cancer who carry a germline BRCA1 or BRCA2 pathogenic or likely pathogenic variant (gBRCA) in both the metastatic and adj
Externí odkaz:
https://doaj.org/article/ee4cdd610eed4da9bf33a007b3b92391
Autor:
Aurore Carrot, Reza-Thierry Elaidi, Olivier Colomban, Denis Maillet, Michel Tod, Benoit You, Stéphane Oudard
Publikováno v:
Cancers, Vol 14, Iss 3, p 815 (2022)
Background: In metastatic prostate cancer (PCa) patients, androgen-deprivation therapy (ADT) combined with chemotherapy or next-generation androgen receptor targeted agents is a new standard treatment. The objective of the present study is to assess
Externí odkaz:
https://doaj.org/article/8d2e59e787c24d5fadfdb22a3210f95e
Autor:
Bastien Collomb, Amélie Dubromel, Anne Gaëlle Caffin, Chloé Herledan, Virginie Larbre, Amandine Baudouin, Ariane Cerutti, Laurence Couturier, Magali Maire, Lionel Karlin, Delphine Maucort-Boulch, Laure Huot, Stéphane Dalle, Emmanuel Bachy, Hervé Ghesquieres, Gilles Salles, Sébastien Couraud, Benoit You, Gilles Freyer, Véronique Trillet-Lenoir, Florence Ranchon, Catherine Rioufol
Publikováno v:
Cancers, Vol 14, Iss 3, p 660 (2022)
Background In previous studies, patient-reported outcomes (PROs) have been shown to improve survival in cancer patients. The aim of the present study was to assess symptoms potentially related to adverse events experienced by cancer outpatients treat
Externí odkaz:
https://doaj.org/article/92477568c5d94e4ab6aeab873c6d10e6
Autor:
Ambroise Lauby, Olivier Colomban, Pauline Corbaux, Julien Peron, Lilian Van Wagensveld, Witold Gertych, Naoual Bakrin, Pierre Descargues, Jonathan Lopez, Vahan Kepenekian, Olivier Glehen, Charles Andre Philip, Mojgan Devouassoux-Shisheboran, Michel Tod, Gilles Freyer, Benoit You
Publikováno v:
Cancers, Vol 14, Iss 1, p 98 (2021)
Ovarian cancer is the gynecological cancer with the worst prognosis and the highest mortality rate because 75% of patients are diagnosed with advanced stage III–IV disease. About 50% of patients are now treated with neoadjuvant chemotherapy followe
Externí odkaz:
https://doaj.org/article/a2929bd7a3ec45a7b50b8e37fc9ad34a